Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 11/20 | 0.45 |
| ▸ | HTR7 | P34969 | 11/20 | 0.45 |
| ▸ | HTR6 | P50406 | 7/20 | 0.45 |
| ▸ | DRD2 | P14416 | 7/20 | 0.45 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.43 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 3/20 | 0.42 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.42 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1730433 | 0.97 | HTR1A (0.47) | HTR1AHTR7HTR6DRD2EPAS1 | |
| SCHEMBL1728654 | 0.92 | KDM4E (0.49) | HTR1AHTR7NFE2L2EPHX2L3MBTL1 | |
| SCHEMBL1730942 | 0.89 | EPAS1 (0.45) | HTR1AHTR7HTR6DRD2EPAS1 | |
| SCHEMBL1730436 | 0.89 | HTR1A (0.50) | HTR1AHTR7HTR6DRD2EPHX2 | |
| SCHEMBL4174270 | 0.89 | HTR1A (0.50) | HTR1AHTR7HTR6DRD2L3MBTL1 | |
| SCHEMBL1730296 | 0.88 | HTR1A (0.46) | HTR1AHTR7HTR6DRD2NFE2L2 | |
| SCHEMBL1730234 | 0.86 | EPAS1 (0.47) | HTR1AHTR7HTR6DRD2EPAS1 | |
| SCHEMBL1730314 | 0.85 | HTR1A (0.53) | HTR1AHTR7HTR6DRD2L3MBTL1 | |
| SCHEMBL1728660 | 0.85 | HTR1A (0.48) | HTR1AHTR7HTR6DRD2HTR2A | |
| SCHEMBL4182228 | 0.83 | LTA4H (0.55) | HTR1AHTR7DRD2EPHX2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221607-A1 | Piperazine Derivatives | M'S SCIENCE CORPORATION (JP) | 2009-09-03 | — | — | US | claimed |
| EP-1988902-B1 | PIPERAZINE DERIVATIVES | MS SCIENCE CORP (JP) | 2011-11-23 | — | — | EP | disclosed |
| US-20090221607-A1 | Piperazine Derivatives | M'S SCIENCE CORPORATION (JP) | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221607-A1 | Piperazine Derivatives | SIGMAR1, OPRL1, OPRK1 | HTR1A 25/4885HTR7 170/4885HTR6 197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.